Abivax

Research Abivax (ABVX) on Bullrun: market cap USD 7.66B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerABVX
• ExchangeNASDAQ
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 7.66B
• Financial periodQ1 2026
• Net income-USD 48.47M
• Free cash flow-USD 50.57M

Valuation Snapshot

latest market cap is USD 7.66B.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Frequently asked questions

What is Abivax's market cap?

Abivax's market capitalization is USD 7.66B.

What does Abivax do?

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.